These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32048159)

  • 1. Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
    José JM; Jose M; Silverio R; Federico V; Isabel C; Martin OA; Inmaculada B; Cristina C; Julia HC; Dolores TM; Jose G; Paola P; Nieves DP; Vicent A; Sara B; Sara M; Julián L; Manuel S; Del Carmen MM; Ángel CM; Vicente G
    Clin Transl Oncol; 2020 Sep; 22(9):1517-1523. PubMed ID: 32048159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
    Hinata N; Yonese J; Masui S; Nakai Y; Shirotake S; Tatsugami K; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Ochi K; Kaneko H; Uemura H
    Int J Clin Oncol; 2020 Aug; 25(8):1533-1542. PubMed ID: 32519026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study.
    Işık D; Kınıkoğlu O; Akdağ G; Altıntaş YE; Türkoğlu E; Yildirim S; Sürmeli H; Başoğlu T; Odabaş H; Turan N
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064516
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.
    Amores Bermúdez J; Osman García I; Unda Urzáiz M; Jiménez Marrero P; Ledo Cepero MJ; Llarena R; Flores Martín J; Abad Vivas-Pérez JI; Rodrigo Aliaga M; Juarez Soto A
    Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):364-370. PubMed ID: 31097211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.
    Mollica V; Rizzo A; Tassinari E; Giunchi F; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Anticancer Drugs; 2021 Jan; 32(1):74-81. PubMed ID: 33290315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
    Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
    Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?
    Ocak B; Sahin AB; Ertürk I; Korkmaz M; Erdem D; Cakıroglu U; Karaca M; Dirican A; Olmez OF; Goktas Aydın S; Gökyer A; Kücükarda A; Gülmez A; Yumuk PF; Demircan NC; Oyman A; Sakalar T; Karatas F; Demir H; Yasin AI; Deligonul A; Dakiki B; Goktug MR; Avcı O; Tacar SY; Turhal NS; Deniz GI; Kacan T; Cubukcu E; Evrensel T
    Curr Oncol; 2024 Sep; 31(9):5195-5205. PubMed ID: 39330012
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review.
    Yonese J; Hinata N; Masui S; Nakai Y; Shirotake S; Takeuchi A; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Morishima N; Ito H; Uemura H
    Int J Urol; 2023 Sep; 30(9):762-771. PubMed ID: 37248753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.
    Barthélémy P; Albigès L; Escudier B; Narciso B; Bigot P; Chehimi M; Emambux S; Calcagno F; Mouillet G; Eymard JC; Schlürmann F; Bailly S; Garbay D; Berdah JF; Palmaro MB; Goupil MG; Spaeth D; Néré S; Quentric C; Vano YA; Thiery-Vuillemin A
    ESMO Open; 2024 Jul; 9(7):103602. PubMed ID: 38897136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
    Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
    Messina C; Catalano M; Roviello G; Gandini A; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucal PA; Masini C; Naglieri E; Procopio G; Milella M; Catalano F; Fratino L; Pipitone S; Ricotta R; Panni S; Mollica V; Soraru M; Prati V; Atzori F; Di Napoli M; Messina M; Morelli F; Prati G; Nole F; Malgeri A; Tudini M; Vignani F; Cavo A; Signori A; Banna GL; Rescigno P; Buti S; Rebuzzi SE; Fornarini G
    Cancer Immunol Immunother; 2024 Jul; 73(9):161. PubMed ID: 38954006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.
    Gamulin M; Nham E; Rkman D; Antunac Golubić Z; Likić R
    Croat Med J; 2020 Aug; 61(4):326-332. PubMed ID: 32881430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.